Jefferies assumed coverage of Ascendis Pharma (ASND) with a Buy rating and $290 price target The companyhas three approved products powered by its TransCon platform, the analyst tells investors in a research note. The firm views Ascendis as a “two-engine growth story” with Yorvipath still on a “hot growth trajectory” and Yuviwel positioned to “disrupt” achondroplasia in the near term.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma announces new data from Navepegritide trial
- Ascendis Pharma: Durable Endocrine Franchise Growth and Emerging Pipeline Upside Support Buy Rating
- Ascendis Pharma price target raised to $332 from $325 at Stifel
- Ascendis Pharma price target raised to $275 from $250 at RBC Capital
- Ascendis Pharma Wins FDA Accelerated Approval for YUVIWEL in Pediatric Achondroplasia